News - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

76 to 100 of 421 results

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

17-03-2014

The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

Pharma Summit: AIDS activists picket to demand South African reform

Pharma Summit: AIDS activists picket to demand South African reform

14-03-2014

Delegates at The Economist’s Pharma Summit in London yesterday were greeted by AIDS activists picketing…

Anti-viralsFinancialLegalPharmaceuticalPricingSouth AfricaUK

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

14-03-2014

US drugmaker Idenix Pharmaceuticals says it has filed patent infringement law suits against biotech firm…

Anti-viralsBiotechnologyGilead SciencesIdenix PharmaceuticalsLegalNorthern EuropePatentssofosbuvirSovaldi

India/USA trade dispute could impact AIDS treatment programs

10-03-2014

The trade dispute over intellectual property rights between the USA and India is set to derail the distribution…

Anti-viralsCiplaGenericsGilead SciencesGlaxoSmithKlineIndiaPatentsPricingUSA

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

Positive new results for Merck’s Isentress in HIV-1 presented at CROI 2014

07-03-2014

USA pharma giant Merck & Co subsidiary MSD says that in a 96-week, open-label AIDS Clinical Trials Group…

Anti-viralsIsentressMerck & CoPharmaceuticalResearch

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

06-03-2014

German family-owned pharma major Boehringer Ingelheim announced positive results from STARTVerso 4 in…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

“Overwhelming approval” in store for Heplisav if Dynavax delivers sufficient safety data, says analyst

“Overwhelming approval” in store for Heplisav if Dynavax delivers sufficient safety data, says analyst

27-02-2014

Despite citing the need for further safety studies, both US and EU regulators have lauded the immunogenicity…

Anti-viralsBiotechnologyDynavax TechnologiesHeplisavRegulationResearchVaccines

FDA Breakthrough designation for all-oral daclatasvir for chronic hepatitis C

24-02-2014

The US Food and Drug Administration has granted drug major Bristol-Myers Squibb’s investigational DCV…

Anti-viralsBristol-Myers SquibbdaclatasvirNorth AmericaPharmaceuticalRegulationUSA

Merck & Co partners with Cipla for Indian marketing of raltegravir

Merck & Co partners with Cipla for Indian marketing of raltegravir

21-02-2014

US pharma giant Merck & Co, known as MSD outside North America, has announced the formation of an India-specific…

Anti-viralsAsia-PacificCiplaIndiaIsentressMarkets & MarketingMerck & CoPharmaceuticalRaltegravir Tablets

AHF claims victory over FDA on Gilead’s PrEP

19-02-2014

The USA-based AIDS Healthcare Foundation (AHF) says it has won another key legal victory late last week…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaRegulationTruvadaUSA

Dynavax withdraws European MAA for Heplisav

18-02-2014

US biotech firm Dynavax Technologies says it has withdrawn the European Marketing Authorization Application…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Creation of ABIVAX - a leader in therapeutic vaccines - in a Cuban collaboration

12-02-2014

French venture capital firm Truffle Capital has announced the creation of Paris-based ABIVAX in collaboration…

ABIVAXAnti-viralsBiotechnologyResearchVaccines

Modest growth expected for hepatitis B vaccine market

Modest growth expected for hepatitis B vaccine market

12-02-2014

The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming…

Anti-viralsDynavax TechnologiesHeplisavHexyonMarkets & MarketingPharmaceuticalSanofiSanofi Pasteur MSDVaccines

Putting patients first is a win-win situation

Putting patients first is a win-win situation

07-02-2014

Here's our take on the week's top stories.

Anti-viralsPharmaceuticalTivicayUKViiV Healthcare

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

07-02-2014

US biotech Gilead Sciences has indicated it would charge $2,000 per 24 week treatment course for the…

Anti-viralsBiotechnologyGilead SciencesGlobalIndiaPricingsofosbuvirSovaldi

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

03-02-2014

Global HIV company Viiv Healthcare has launched its first new treatment option for people with HIV today.

Anti-viralsAtriplaInterviewsIsentressPharmaceuticalPrezistaRegulationResearchTivicayUKViiV Healthcare

Mylan gets exclusive rights to distribute Gilead branded drugs in India

Mylan gets exclusive rights to distribute Gilead branded drugs in India

31-01-2014

US generics major Mylan says its India-based subsidiary has been named) exclusive branded medicines business…

AmbisomeAnti-viralsAsia-PacificBiotechnologyGilead SciencesIndiaMarkets & MarketingMylan LaboratoriesStribildTruvadaViread

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

30-01-2014

In a series of letters to be sent to state Medicaid directors starting this week, Michael Weinstein,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingSovaldiUSA

Janssen sets up new group targeting unmet global health needs

Janssen sets up new group targeting unmet global health needs

22-01-2014

US health care giant Johnson & Johnson’s Janssen companies are forming Janssen Global Public Health,…

Anti-viralsAntibiotics and Infectious diseasesJanssenJohnson & JohnsonPharmaceuticalResearch

ViiV Healthcare’s new HIV medicine Tivicay is approved in Europe

21-01-2014

The European Commission has approved Tivicay (dolutegravir) made by Viiv Healthcare for use in combination…

Anti-viralsEuropePharmaceuticalResearchTivicayViiV Healthcare

BiondVax’ universal flu vaccine matches all six potentially pandemic flu strains in the world

21-01-2014

BiondVax Pharmaceuticals, an Israeli company developing a universal flu vaccine, says it has completed…

Anti-viralsBiondVaxPharmaceuticalResearchVaccines

iCo Therapeutics within reach of ‘holy grail’ cure in the $14 billion HIV market, says Edison

20-01-2014

Canadian biotech company iCo Therapeutics’s (iCO: TSX-V) compound AmpB could potentially allow the…

Anti-viralsBiotechnologyCanadaFinancialiCo TherapeuticsResearch

Gilead’s Sovaldi gains EC approval for chronic hepatitis C

Gilead’s Sovaldi gains EC approval for chronic hepatitis C

20-01-2014

US antivirals specialist Gilead Sciences has received marketing authorization from the European Commission…

Anti-viralsBiotechnologyEuropeGilead SciencesPricingRegulationSovaldi

76 to 100 of 421 results

Back to top